REGULATORY AFFAIRS
Answers to the most-searched questions about the regulatory affairs profession, its scope, and how organisations engage regulatory consulting support.
Q1: What does regulatory affairs mean and what does a regulatory affairs professional do?
A: Regulatory affairs (RA) is the discipline that ensures pharmaceutical, biotech, and medical device products meet all applicable legal and scientific requirements for market authorisation, post-approval maintenance, and ongoing lifecycle management. RA professionals act as the bridge between science, law, and commerce preparing and submitting dossiers to health authorities, managing agency interactions, monitoring regulatory intelligence, and ensuring compliance with labelling, advertising, and pharmacovigilance obligations. In practice, the role spans strategy (deciding the optimal regulatory pathway), operations (authoring, compiling, and submitting CTD/eCTD dossiers), and governance (maintaining approved product data, tracking variations, and responding to agency queries).
Q2: What is the difference between regulatory affairs and regulatory compliance?
A: Regulatory affairs focuses on achieving and maintaining product authorisation securing approvals from agencies such as the EMA, FDA, CDSCO, TGA, or MHRA. Regulatory compliance, by contrast, focuses on ensuring ongoing adherence to all applicable laws, guidelines, and standards across the organisation including GMP/GDP for manufacturing, GCP for clinical trials, and GVP for pharmacovigilance. In practice, the two functions overlap significantly. Regulatory gap analysis and remediation services sit at this intersection, helping organisations identify where operations have diverged from current regulatory expectations and implement corrective actions before an inspection or audit reveals those gaps.
Q3: What is an eCTD and why is it now the global standard for drug submissions?
A: The electronic Common Technical Document (eCTD) is the internationally harmonised format for submitting regulatory dossiers to health authorities. Defined under ICH M4, the eCTD organises product information into five modules: Module 1 (regional administrative/prescribing information), Module 2 (summaries and overviews), Module 3 (quality/CMC), Module 4 (nonclinical study reports), and Module 5 (clinical study reports). The format is now mandatory or strongly preferred by the EMA, FDA, Health Canada, TGA, and a growing number of national agencies. Its standardised, XML-based structure enables consistent lifecycle management variations, renewals, and safety updates are tracked as sequences on the same dossier, providing a full history of regulatory activity throughout a product’s life.
Q4: What regulatory pathways are available for bringing a new drug to market in the EU?
A: The EU offers four main procedures. The Centralised Procedure (CP), compulsory for certain product categories (biologics, oncology, HIV, orphan medicines) and optional for others, results in a single EMA Committee for Medicinal Products for Human Use (CHMP) opinion and a pan-EU marketing authorisation valid in all 27 member states plus EEA countries. The Mutual Recognition Procedure (MRP) allows an approval in one Reference Member State (RMS) to be recognised by other Concerned Member States (CMS). The Decentralised Procedure (DCP) enables simultaneous assessment across multiple member states with one RMS leading. The National Procedure is available only for products intended for a single member state. Orphan drug designation, PRIME eligibility, and conditional or exceptional circumstances approvals can overlay these pathways to accelerate access for medicines addressing unmet needs.
Q5: How do regulatory affairs consulting firms add value to pharmaceutical and biotech companies?
A: Regulatory consulting firms provide external expertise that fills capability or capacity gaps within sponsor organisations. Value is delivered in several ways: strategic advice on optimal development and submission pathways before significant R&D investment is made; authoring and compiling regulatory dossiers to the standard expected by target agencies; managing health authority interactions and queries on behalf of MAHs; conducting regulatory intelligence to anticipate changes in the legislative or guidance landscape; and providing interim or outsourced QPPV, Regulatory Lead, or Regulatory Operations functions. For smaller companies and virtual biotechs without an established RA function, a specialist consulting partner effectively acts as the external regulatory department. For large pharma, consultants are deployed on surge projects, market expansions, or specialist submissions where in-house bandwidth is insufficient.
Q6: What are the most common reasons drug applications are refused or receive a negative CHMP opinion?
A: EMA CHMP refusals most commonly result from one of three deficiencies: unresolved questions about clinical efficacy (inadequate trial design, missing subgroup data, or a failure to demonstrate a meaningful benefit-risk balance); manufacturing quality concerns (insufficient process validation, impurity data, or drug product stability); or pharmacovigilance inadequacies (an incomplete or unsubstantiated risk management plan). A Withdrawn Application where a sponsor voluntarily withdraws before a formal refusal often signals similar issues identified during Day 120/180 questions. Understanding these common failure modes informs both the quality of the initial application and the robustness of pre-submission scientific advice sought from agencies.
Q7: What is scientific advice and when should a company seek it from a health authority?
A: Scientific advice (SA) is a formal mechanism by which product sponsors can seek guidance from health authorities on methodological, clinical, quality, or non-clinical questions before or during product development. In the EU, EMA offers parallel scientific advice (coordinating input from multiple NCAs), joint scientific advice (with EMA and MHRA post-Brexit), and early dialogue programmes such as PRIME for breakthrough therapies. FDA equivalents include Pre-IND meetings, End-of-Phase-2 (EOP2) meetings, and Pre-NDA/BLA meetings. SA is most valuable when pivotal trial design is being finalised, when an unconventional regulatory pathway is being considered, or when specific quality or non-clinical concerns may affect approvability. Proactive engagement substantially reduces the risk of late-stage surprises.
Q8: What is regulatory intelligence and why do companies invest in it?
A: Regulatory intelligence (RI) is the systematic monitoring and analysis of evolving regulations, guidelines, agency decisions, and policy developments across global markets. Companies invest in RI to anticipate changes that affect development strategy, product labelling, manufacturing standards, or post-marketing obligations enabling proactive adaptation rather than reactive remediation. RI outputs include horizon-scanning reports, regulatory impact assessments, gap analyses triggered by new guidance, and competitive landscape tracking (approved products, agency precedents, orphan designations). In fast-moving therapeutic areas or markets undergoing legislative reform such as the EU AI Act’s implications for software as a medical device (SaMD) or ongoing FDA guidance updates on cell and gene therapies robust RI is a material competitive advantage.
Comments are closed